Uncompassionate use: the inconsistent offering of life-saving unlicensed medicines
The Pharmaceutical Journal from the Royal Pharmaceutical Society
Source: pharmaceutical-journal.com
📰 Access Pathway News
Page 6 - Access Pathway News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Access Pathway. Real-time updates on events, politics, business and more.
MHRA marketing authorization granted to Amicus' Pompe disease treatment
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Pombliti + Opfolda, a two-component therapy to treat Pompe disease.
Source: outsourcing-pharma.com
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million tied to exercise of warrants Net proceeds... -Today at 08:59 am- MarketScreener
Source: marketscreener.com
COMPASS Pathways Announces Up to $285 Million Private
 Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million...
Source: globenewswire.com
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading ...
Transaction led by healthcare specialist investors, TCGX and Aisling Capital
Source: eagletribune.com
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
-FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT); Priority Review for SCD and Standard Review for TDT- -PDUFA target action date of December 8, 2023, for SCD and March 30, 2024, for TDT- -Enrollment and dosing ongoing for CTX110®, targeting CD19+ B-cell malignancies, and CTX130™, targeting CD70 for the treatment of T cell lymphomas- -Enrollment ongoing and d...
Source: yahoo.com
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
COMP360 psilocybin treatment shows potential in exploratory open-label investigator-initiated study in anorexia nervosaLONDON, July 25, 2023 -- COMPASS Pathways plc , a biotechnology company...
Source: marketscreener.com
Latest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 202
STOCKHOLM, July 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...
Source: europapress.es
Eisai Presents Latest Analysis of Lecanemab's Effect on
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer’s disease ...
Source: globenewswire.com
Latest analysis of lecanemab's effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference
/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results of a detailed analysis of the Phase 3 Clarity...
Source: prnewswire.com